Synthesis and ABCG2 inhibitory activity of novel fumitremorgin C analogs-specificity and structure activity correlations

Orsolya Szolomajer-Csikós, Erzsébet Beéry, Levente Kósa, Zsuzsanna Rajnai, Márton Jani, A. Hetényi, Katalin Tauber Jakab, Péter Krajcsi, G. Tóth

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The Ko family of fumitremorgin C analogs are potent and selective ABCG2 inhibitors. However, the most potent Ko compounds carry an ester linkage in their side-chain that makes them chemically and metabolically less stable. We have synthesized 16 tricyclic and 28 tetracyclic novel analogs devoid of ester linkages and tested them for ABCG2 inhibition potency and specificity. Unlike in the tricyclic analog group, potent ABCG2 inhibitory compounds were found among the tetracyclic analogs. The most potent compounds carried the 3S,6S,12aS configuration. We observed a marked stereospecificity as compounds with the 3S,6S,12aS configuration were at least 18-fold more potent inhibitors than their diastereoisomeric pairs with a 3S,6R,12aS configuration. This stereospecificity was not observed in ABCB1 and ABCC1 inhibition. Therefore, a single chiral center confers specificity for ABCG2 over ABCB1 and ABCC1. This is quite unexpected considering the large multivalent drug binding site these transporters harbor.

Original languageEnglish
Pages (from-to)494-509
Number of pages16
JournalMedicinal Chemistry
Volume9
Issue number4
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Esters
Binding Sites
Pharmaceutical Preparations
tryptoquivaline

Keywords

  • ABCG2 reversal
  • Cancer
  • Fumitremorgin C analogs
  • Indolyl diketopiperazines
  • Inflammatory diseases
  • Multidrug resistance
  • Structure-activity relationships

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Synthesis and ABCG2 inhibitory activity of novel fumitremorgin C analogs-specificity and structure activity correlations. / Szolomajer-Csikós, Orsolya; Beéry, Erzsébet; Kósa, Levente; Rajnai, Zsuzsanna; Jani, Márton; Hetényi, A.; Jakab, Katalin Tauber; Krajcsi, Péter; Tóth, G.

In: Medicinal Chemistry, Vol. 9, No. 4, 06.2013, p. 494-509.

Research output: Contribution to journalArticle

Szolomajer-Csikós, Orsolya ; Beéry, Erzsébet ; Kósa, Levente ; Rajnai, Zsuzsanna ; Jani, Márton ; Hetényi, A. ; Jakab, Katalin Tauber ; Krajcsi, Péter ; Tóth, G. / Synthesis and ABCG2 inhibitory activity of novel fumitremorgin C analogs-specificity and structure activity correlations. In: Medicinal Chemistry. 2013 ; Vol. 9, No. 4. pp. 494-509.
@article{9cd380f0a6bc46cd8ae74b8333bac2c9,
title = "Synthesis and ABCG2 inhibitory activity of novel fumitremorgin C analogs-specificity and structure activity correlations",
abstract = "The Ko family of fumitremorgin C analogs are potent and selective ABCG2 inhibitors. However, the most potent Ko compounds carry an ester linkage in their side-chain that makes them chemically and metabolically less stable. We have synthesized 16 tricyclic and 28 tetracyclic novel analogs devoid of ester linkages and tested them for ABCG2 inhibition potency and specificity. Unlike in the tricyclic analog group, potent ABCG2 inhibitory compounds were found among the tetracyclic analogs. The most potent compounds carried the 3S,6S,12aS configuration. We observed a marked stereospecificity as compounds with the 3S,6S,12aS configuration were at least 18-fold more potent inhibitors than their diastereoisomeric pairs with a 3S,6R,12aS configuration. This stereospecificity was not observed in ABCB1 and ABCC1 inhibition. Therefore, a single chiral center confers specificity for ABCG2 over ABCB1 and ABCC1. This is quite unexpected considering the large multivalent drug binding site these transporters harbor.",
keywords = "ABCG2 reversal, Cancer, Fumitremorgin C analogs, Indolyl diketopiperazines, Inflammatory diseases, Multidrug resistance, Structure-activity relationships",
author = "Orsolya Szolomajer-Csik{\'o}s and Erzs{\'e}bet Be{\'e}ry and Levente K{\'o}sa and Zsuzsanna Rajnai and M{\'a}rton Jani and A. Het{\'e}nyi and Jakab, {Katalin Tauber} and P{\'e}ter Krajcsi and G. T{\'o}th",
year = "2013",
month = "6",
doi = "10.2174/1573406411309040003",
language = "English",
volume = "9",
pages = "494--509",
journal = "Medicinal Chemistry",
issn = "1573-4064",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Synthesis and ABCG2 inhibitory activity of novel fumitremorgin C analogs-specificity and structure activity correlations

AU - Szolomajer-Csikós, Orsolya

AU - Beéry, Erzsébet

AU - Kósa, Levente

AU - Rajnai, Zsuzsanna

AU - Jani, Márton

AU - Hetényi, A.

AU - Jakab, Katalin Tauber

AU - Krajcsi, Péter

AU - Tóth, G.

PY - 2013/6

Y1 - 2013/6

N2 - The Ko family of fumitremorgin C analogs are potent and selective ABCG2 inhibitors. However, the most potent Ko compounds carry an ester linkage in their side-chain that makes them chemically and metabolically less stable. We have synthesized 16 tricyclic and 28 tetracyclic novel analogs devoid of ester linkages and tested them for ABCG2 inhibition potency and specificity. Unlike in the tricyclic analog group, potent ABCG2 inhibitory compounds were found among the tetracyclic analogs. The most potent compounds carried the 3S,6S,12aS configuration. We observed a marked stereospecificity as compounds with the 3S,6S,12aS configuration were at least 18-fold more potent inhibitors than their diastereoisomeric pairs with a 3S,6R,12aS configuration. This stereospecificity was not observed in ABCB1 and ABCC1 inhibition. Therefore, a single chiral center confers specificity for ABCG2 over ABCB1 and ABCC1. This is quite unexpected considering the large multivalent drug binding site these transporters harbor.

AB - The Ko family of fumitremorgin C analogs are potent and selective ABCG2 inhibitors. However, the most potent Ko compounds carry an ester linkage in their side-chain that makes them chemically and metabolically less stable. We have synthesized 16 tricyclic and 28 tetracyclic novel analogs devoid of ester linkages and tested them for ABCG2 inhibition potency and specificity. Unlike in the tricyclic analog group, potent ABCG2 inhibitory compounds were found among the tetracyclic analogs. The most potent compounds carried the 3S,6S,12aS configuration. We observed a marked stereospecificity as compounds with the 3S,6S,12aS configuration were at least 18-fold more potent inhibitors than their diastereoisomeric pairs with a 3S,6R,12aS configuration. This stereospecificity was not observed in ABCB1 and ABCC1 inhibition. Therefore, a single chiral center confers specificity for ABCG2 over ABCB1 and ABCC1. This is quite unexpected considering the large multivalent drug binding site these transporters harbor.

KW - ABCG2 reversal

KW - Cancer

KW - Fumitremorgin C analogs

KW - Indolyl diketopiperazines

KW - Inflammatory diseases

KW - Multidrug resistance

KW - Structure-activity relationships

UR - http://www.scopus.com/inward/record.url?scp=84877935459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877935459&partnerID=8YFLogxK

U2 - 10.2174/1573406411309040003

DO - 10.2174/1573406411309040003

M3 - Article

VL - 9

SP - 494

EP - 509

JO - Medicinal Chemistry

JF - Medicinal Chemistry

SN - 1573-4064

IS - 4

ER -